Emerald Health Therapeutics Inc (CVE:EMH) posted an update on its closed and oversubscribed procured agreement financing, and echoes its goal for 2017. Avtar Dhillon, who is the Executive Chairman, revealed that following this positive agreement with Dundee Capital Partners, they are all equipped for a robust year of development.
Headed by one of the most brilliant teams, the emphasis is on downstream offerings progress. Right from the start, Emerald Health has shadowed the mandate of improving health applying Cannabis Science and then it is the set standards that will through them with aggressive and exhilarating growth strategies. It appears the company is all set to benefit from its plans.
As Emerald has been pointing expansion, a big part of its attention is on increasing offerings and exhibiting plant diversity, as well as succeeding on its grow, production, and control mechanisms in hope of a general scale up. As one of the LPs, right from the start the extreme focus has lingered on grow quality contrary to quantity reinforced by R&D.
The growth plans of Phase 1 are continuing to jump in the first quarter and get more farming space. It will be a cutting-edge built facility with foreseen capacity of over 5,000 kg annually. The firm’s first yield is forecasted in 2018 and will be primed for sale upon licensing. Concerning growth of Phase II, Emerald proposes to cultivate in segmental means, with addition of increased area for lessening quality concerns.
Construction on Phase II will augment another production area of 50,000 square feet. It is awaited to instigate after the initiation of Phase 1 and will be primed for production in forthcoming year. Emerald possess the propensity to establish production space of one million sq. ft. on Metro Vancouver property. It remains to seen how the planned programs progresses in the coming period.